Gearing
Andrew John Hubert Gearing, Victoria AU
Patent application number | Description | Published |
---|---|---|
20090087410 | TREATMENT OF HYPERSENSITIVITY - The present invention relates to a method for inhibiting a hypersensitivity reaction in a subject, wherein said method comprises administering an effective amount of chaperonin (10). | 04-02-2009 |
Brian P. Gearing, Berkeley, CA US
Patent application number | Description | Published |
---|---|---|
20080228280 | Tribological Applications of Polyelectrolyte Multilayers - One aspect of the present invention relates to an implantable medical device comprising a surface coated with a polyelectrolyte multilayer, wherein said surface is glass, metal, plastic, polymer, or fiberglass. Another aspect of the present invention involves a method of preparing a PEM-coated implantable medical device, comprising the step of applying a film to a surface of an implantable medical device, wherein said film comprises a polyelectrolyte multilayer and said surface is glass, metal, plastic, polymer, or fiberglass. Another aspect of the present invention involves a method of reducing the wear between two contacting materials, comprising the step of moving a first material in contact with a second material in an environment, wherein a first surface of said first material is in contact with a second surface of said second material, wherein said first surface, said second surface, or both is coated with a polyelectrolyte multilayer, thereby decreasing the wear of said first material, said second material, or both compared to the wear in the absence of said polyelectrolyte multilayer. | 09-18-2008 |
David Gearing, Southbank AU
Patent application number | Description | Published |
---|---|---|
20140147439 | ANTI-NERVE GROWTH FACTOR ANTIBODIES AND METHODS OF PREPARING AND USING THE SAME - A method of preparing an antibody suitable for use in a feline is provided. Also provided are chimeric and felinised antibodies which specifically bind to feline neuronal growth factor (NGF) and neutralise the ability of feline NGF to bind to the p75 or TrkA feline NGF receptor. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in a feline using said antibodies and/or nucleic acids. | 05-29-2014 |
20140170136 | ANTI-NERVE GROWTH FACTOR ANTIBODIES AND METHODS OF PREPARING AND USING THE SAME - A method of preparing an antibody suitable for use in an equine is provided. Also provided are equinised antibodies which specifically bind to equine neuronal growth factor (NGF) and neutralise the ability of equine NGF to bind to the p75 or TrkA equine NGF receptor. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in an equine using said antibodies and/or nucleic acids. | 06-19-2014 |
20140170137 | THERAPEUTIC CANINE IMMUNOGLOBULINS AND METHODS OF USING SAME - A method of preparing a canine antibody suitable for use in the therapeutic treatment of a canine is provided. In particular, there is provided immunoglobulins which can be selected for the characteristic of whether they mediate downstream complement mediated immune activation when bound to a target antigen. Canine derived antibodies comprising specific heavy chain isotypes are provided. The invention extends to the use of the immunoglobulins of the invention in methods of treating conditions such as pain, inflammatory conditions and cancerous conditions in a canine. | 06-19-2014 |
20140294815 | CANINISED TUMOUR NECROSIS FACTOR ANTIBODIES AND METHODS OF USING THE SAME - Caninised and chimeric antibodies and antigen binding fragments thereof which bind specifically to canine tumour necrosis factor and inhibit the ability of canine TNF to bind to the TNFR1 receptor are provided. The invention further extends to nucleic acids encoding same and to methods of treating chronic inflammatory disease such as arthritis in a canine using said antibodies and/or nucleic acids. | 10-02-2014 |
20150056183 | THERAPEUTIC CANINE IMMUNOGLOBULINS AND METHODS OF USING SAME - A method of preparing a canine antibody suitable for use in the therapeutic treatment of a canine is provided. In particular, there is provided immunoglobulins which can be selected for the characteristic of whether they mediate downstream complement mediated immune activation when bound to a target antigen. Canine derived antibodies comprising specific heavy chain isotypes are provided. The invention extends to the use of the immunoglobulins of the invention in methods of treating conditions such as pain, inflammatory conditions and cancerous conditions in a canine. | 02-26-2015 |
David Gearing, Melbourne AU
Patent application number | Description | Published |
---|---|---|
20140294819 | CANINE/FELINE CD20 BINDING EPITOPE AND COMPOSITIONS FOR BINDING THERETO - The present invention provides acyclic polypeptide fragment of CD20 comprising (i) a contiguous amino acid sequence consisting of amino acid residues SEKNS (SEQ ID NO:67); (ii) a first cysteine residue which is present at a region N-terminal to the contiguous amino acid sequence and (iii) a second cysteine residue which is present at a region C-terminal to the contiguous amino acid sequence, wherein the cyclic polypeptide is oxidised by the presence of a disulphide bond formed between the first and second cysteine residues. Also described is the use of the cyclic peptide fragment to generate antibodies which bind specifically to CD20. Antibodies which bind specifically to the cyclic peptide fragment for use in treatment of B-cell mediated conditions in felines and canines are also described. | 10-02-2014 |
20140328838 | CANINISED ANTIBODIES AND METHOD FOR PRODUCTION OF SAME - A method of producing a non-immunogenic immunoglobulin for administration to a target species is provided wherein the method comprises substituting amino acid residues in framework regions of a donor immunoglobulin with amino acid residues present at a corresponding position in framework regions of at least one immunoglobulin derived from the target species. Also provided are antibodies produced by the method of the invention, including novel humanised and caninised anti-NGF antibodies. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in a human or dog using said antibodies and/or nucleic acids. | 11-06-2014 |
20150037333 | TUMOUR NECROSIS FACTOR RECEPTOR FUSION PROTEINS AND METHODS OF USING THE SAME - A chimeric fusion polypeptide is provided comprising an extracellular domain of a canine TNF receptor p60 or p80 polypeptide conjoined to an Fc region of a canine IgG immunoglobulin heavy chain. The chimeric fusion polypeptide may be used in the treatment or prevention of conditions in canines mediated by TNF expression. | 02-05-2015 |
David Gearing, Southbank AT
Patent application number | Description | Published |
---|---|---|
20150017154 | ANTI-NERVE GROWTH FACTOR ANTIBODIES AND METHODS OF PREPARING AND USING THE SAME - A method of preparing an antibody suitable for use in a canine is provided. Also provided are caninised antibodies which specifically bind to canine neuronal growth factor (NGF) and neutralise the ability of canine NGF to bind to the p75 or TrkA canine NGF receptor. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in a canine using said antibodies and/or nucleic acids. | 01-15-2015 |
David P. Gearing, Camberwell AU
Patent application number | Description | Published |
---|---|---|
20080220495 | DELTA3, FTHMA-070, TANGO85, TANGO77, SPOIL, NEOKINE, TANGO129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof - The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 09-11-2008 |
20090286956 | DELTA3, FTHMA-070, TANGO85, TANGO77, SPOIL, NEOKINE, TANGO129, and INTEGRIN ALPHA SUBUNIT Protein and nucleic acid molecules and uses thereof - The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 11-19-2009 |
20110306044 | DELTA3, FTHMA-070, TANGO85, TANGO77, SPOIL, NEOKINE, TANGO129, AND INTEGRIN ALPHA SUBUNIT PROTEIN AND NUCLEIC ACID MOLECULES AND USES THEREOF - The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 12-15-2011 |
20130316343 | DELTA3, FTHMA-070, TANGO85, TANGO77, SPOIL, NEOKINE, TANGO129, AND INTEGRIN ALPHA SUBUNIT PROTEIN AND NUCLEIC ACID MOLECULES AND USES THEREOF - The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 11-28-2013 |
David P. Gearing, Doncaster AU
Patent application number | Description | Published |
---|---|---|
20090117583 | EGF-like nucleic acids and polypeptides and uses thereof - The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1,2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF-α. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. | 05-07-2009 |
David P. Gearing, Victoria AU
Patent application number | Description | Published |
---|---|---|
20080293077 | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses - The invention relates to the discovery and characterization of several genes and the polypeptides they encode: thymotaxin (Tango-45), Tango-63d, Tango-63e, Tango-67, and huchordin (Tango-66). Thymotaxin is a new member of the C-C family of chemokines. Tango-63d and Tango-63e are two novel polypeptides within the tumor necrosis factor (TNF) receptor superfamily. Tango-67 is related to a number of growth factors, particularly members of the connective tissue growth factor family. Huchordin is related to chordin, a known protein that is involved in the induction of twinned axes, can completely rescue axial development in ventralized embryos, is a potent dorsalizing factor, and plays a crucial role in regulating cell-cell interactions in the organizing centers of head, trunk, and tail development. The invention encompasses nucleic acid molecules encoding nucleic acids and polypeptides of the invention, or mutant forms thereof that encode dysfunctional receptor polypeptides, vectors containing these nucleic acid molecules, cells harboring recombinant DNA molecules encoding nucleic acids or polypeptides of the invention, or mutant forms thereof, host fusion proteins that include functional or dysfunctional polypeptides of the invention, transgenic animals that express nucleic acids or polypeptides of the invention, screening methods and therapeutic methods employing the nucleic acid molecules and polypeptides described above, substantially purified nucleic acids and polypeptides of the invention, and therapeutic compositions containing these nucleic acid molecules and polypeptides. | 11-27-2008 |
David Paul Gearing, Victoria AU
Patent application number | Description | Published |
---|---|---|
20110052574 | METHOD OF INHIBITION OF LEUKEMIC STEM CELLS - A method for inhibition of leukemic stem cells expressing IL-3Rα; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3Rα (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule. | 03-03-2011 |
David Paul Gearing, Camberwell AU
Patent application number | Description | Published |
---|---|---|
20130230510 | METHOD OF INHIBITION OF LEUKEMIC STEM CELLS - A method for inhibition of leukemic stem cells expressing IL-3R.alpha.; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R.alpha. (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule. | 09-05-2013 |
20150152185 | METHOD OF INHIBITION OF LEUKEMIC STEM CELLS - A method for inhibition of leukemic stem cells expressing IL-3R.alpha.; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R.alpha. (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule. | 06-04-2015 |
Mark Gearing, Bedfordshire GB
Patent application number | Description | Published |
---|---|---|
20120157275 | METHOD AND SYSTEM FOR DETECTING WEAR IN IMAGING DEVICES - Methods and system for detecting wear in imaging devices. The system includes an outer wearable layer. An inner layer fused to the outer layer. The inner layer is made of multiple microcapsules including odiferous oils. Wearing off of the outer layer, over time, exposes the inner layer. Subsequently, with added pressure on the inner layer, the microcapsules crack, giving off a particular scent. By detecting the smell, customers can identify worn components of the imaging devices. | 06-21-2012 |
Mark Gearing, Bigglesward GB
Patent application number | Description | Published |
---|---|---|
20080317494 | Cleaning head pick-up system - A corotron cleaning assembly includes a self-seating, spring-loaded locating pin drivingly connected to a drive unit that is used to drive a wire cleaning head that is located within a CRU. This assembly allows for easy separation of the drive unit from the cleaner when the CRU that contains the wire is replaced. The bullet shaped pin rides on a worm drive and when the pin is driven into the cleaner head, the bullet hits an inclined ramp and is biased downward until such a point that the pin hits a recessed receptacle. Once the pin is in the receptacle, the pin is capable of driving the wire cleaning head. When the cleaning head is removed, the act of removal separates the pin from the receptacle. | 12-25-2008 |
Mark John Gearing, Bedfordshire GB
Patent application number | Description | Published |
---|---|---|
20130067266 | FAULT-BASED UNIT REPLACEMENT - A method and system are disclosed for determining the end of life condition for a replaceable unit, which may be associated with a multifunction device, and have a useful life expectancy based upon a number of operations. A counter associated with the multifunction device maintains a running count of operations for the unit. Once the number of performed operations of the replaceable unit reaches a given percentage of the expected life of that unit, an analysis is performed on a running history of the fault codes. Once the number of fault codes attributable to any given replaceable unit meets or exceeds a predetermined level, such as a percentage of the running history, a notification is generated indicating a need to replace the replaceable unit. | 03-14-2013 |
Patrick Gearing, North Seattle, WA US
Patent application number | Description | Published |
---|---|---|
20140199302 | COMPOSITIONS FOR REGULATING IRON HOMEOSTASIS AND METHODS OF USING SAME - The present disclosure relates to hemojuvelin-IgG Fc domain fusion proteins, variants, derivatives, fragments and peptide mimetics derived therefrom and methods of using these fusion proteins for the regulation of iron homeostasis and the treatment of diseases related to iron homeostasis. | 07-17-2014 |
Robert Gearing, East Sussex GB
Patent application number | Description | Published |
---|---|---|
20150204479 | REST FOR SUPPORTING AN OBJECT - A rest for supporting an object, the rest comprising: a rest fixture ( | 07-23-2015 |